Literature DB >> 638321

Dopamine receptor mediated inhibition by bromocriptine of accelerator nerve stimulation effects in the pithed cat [proceedings].

G Scholtysik, B Berde.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 638321      PMCID： PMC1668233     

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


× No keyword cloud information.
  4 in total

1.  Stimulant properties of bromocriptine on central dopamine receptors in comparison to apomorphine, (+)-amphetamine and L-DOPA.

Authors:  A M Johnson; D M Loew; J M Vigouret
Journal:  Br J Pharmacol       Date:  1976-01       Impact factor: 8.739

2.  The inhibition of prolactin secretion in man by CB-154 (2-Br-alpha-ergocryptine).

Authors:  E Del Pozo; R B Del Re; L Varga; H Friesen
Journal:  J Clin Endocrinol Metab       Date:  1972-11       Impact factor: 5.958

3.  Further evidence for dopaminoceptors in the vas deferens [proceedings].

Authors:  F M Tayo; G Osuide
Journal:  Br J Pharmacol       Date:  1977-03       Impact factor: 8.739

4.  Effect of ergot drugs on central catecholamine neurons: evidence for a stimulation of central dopamine neurons.

Authors:  H Corrodi; K Fuxe; T Hökfelt; P Lidbrink; U Ungerstedt
Journal:  J Pharm Pharmacol       Date:  1973-05       Impact factor: 3.765
  4 in total
  3 in total

1.  In vivo and in vitro dopaminergic effects of three ergoline fragments.

Authors:  J C Koons; J P Long; J G Cannon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-12       Impact factor: 3.000

Review 2.  Pharmacology of bromocriptine in health and disease.

Authors:  A E Mehta; G Tolis
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

3.  Pharmacodynamic profile of CQP 201-403, a novel 8 alpha-amino-ergoline.

Authors:  E Flückiger; U Briner; B Clark; A Closse; A Enz; P Gull; A Hofmann; R Markstein; L Tolcsvai; H R Wagner
Journal:  Experientia       Date:  1988-05-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.